Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study

High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms

(2014) Olga Pozdnyakova et al.   MODERN PATHOLOGY

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management

(2013) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

World Health Organization-defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations-The Danish experience

(2013) Ann Brinch Madelung et al.   AMERICAN JOURNAL OF HEMATOLOGY

The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes

(2013) Bin Fu et al.   ANNALS OF HEMATOLOGY

Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis

(2013) Tamar Tadmor et al.   CANCER

Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage

(2013) Leonardo Boiocchi et al.   MODERN PATHOLOGY

Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems

(2013) Bin Fu et al.   MODERN PATHOLOGY

Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms

(2013) Umberto Gianelli et al.   MODERN PATHOLOGY

Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome

(2012) T. Barbui et al.   BLOOD

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

(2012) S. Verstovsek et al.   BLOOD

The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis

(2012) Umberto Gianelli et al.   MODERN PATHOLOGY

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents

(2011) Waleed Ghanima et al.   BRITISH JOURNAL OF HAEMATOLOGY

Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities

(2011) Leonardo Boiocchi et al.   MODERN PATHOLOGY

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes

(2008) Matteo Giovanni Della Porta et al.   JOURNAL OF CLINICAL ONCOLOGY